Martin H. van Vliet
Research Subjects
Martin H. van Vliet has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Erik H. van Beers
SkylineDx Rotterdam The Netherlands
3 shared publicationsPieter Sonneveld
Department of Hematology Erasmus MC Cancer Institute Rotterdam the Netherlands
3 shared publications- Jeroen de Ridder
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
2 shared publications - Joske Ubels
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
2 shared publications Rowan Kuiper
SkylineDx Rotterdam The Netherlands
2 shared publicationsAlessandra Larocca
Myeloma Unit Division of Hematology University of Turin Turin Italy
1 shared publication
Latest Publications
- Open Access
- 26 August 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (1) , 127-134
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
Objectives: Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%‐80% of patients are not eligible, possibly limiting the generalizability of findings to routine practice. Here, we evaluate GEP analysis outside clinical trials, aiming to improve clinical risk assessment of multiple myeloma (MM) patients.Methods: A total of 155 bone marrow samples from MM patients were collected from which RNA was analyzed by microarray. Sixteen previously developed GEP‐based markers were evaluated, combined with survival data, and studied using Cox proportional hazard regression.Results: Gene expression profiling‐based markers SKY92 and the PR‐cluster were shown to be independent prognostic factors for survival, with hazard ratios and 95% confidence interval of 3.6 [2.0‐6.8] (P < .001) and 5.8 [2.7‐12.7] (P < .01) for overall survival (OS). A multivariate model proved only SKY92 and the PR‐cluster to be independent prognostic factors compared to cytogenetic high‐risk patients, the International Staging System (ISS), and revised ISS. A substantial number of high‐risk individuals could be further identified when SKY92 was added to the cytogenetic, ISS, or R‐ISS. In the cytogenetic standard‐risk group, ISS I/II, and R‐ISS I/II, 13%, 23%, and 23% of patients with adverse survivals were identified.Conclusions: For the first time, this study confirmed the prognostic value of GEP markers outside clinical trials. Conventional prognostic models to define high‐risk MM are improved by the incorporation of GEP markers.
- 26 August 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (1) , 127-134
Open AccessPrognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
Objectives: Typically, prognostic capability of gene expression profiling (GEP) is studied in the context of clinical trials, for which 50%‐80% of patients are not eligible, possibly limiting the generalizability of findings to routine practice. Here, we evaluate GEP analysis outside clinical trials, aiming to improve clinical risk assessment of multiple myeloma (MM) patients.Methods: A total of 155 bone marrow samples from MM patients were collected from which RNA was analyzed by microarray. Sixteen previously developed GEP‐based markers were evaluated, combined with survival data, and studied using Cox proportional hazard regression.Results: Gene expression profiling‐based markers SKY92 and the PR‐cluster were shown to be independent prognostic factors for survival, with hazard ratios and 95% confidence interval of 3.6 [2.0‐6.8] (P < .001) and 5.8 [2.7‐12.7] (P < .01) for overall survival (OS). A multivariate model proved only SKY92 and the PR‐cluster to be independent prognostic factors compared to cytogenetic high‐risk patients, the International Staging System (ISS), and revised ISS. A substantial number of high‐risk individuals could be further identified when SKY92 was added to the cytogenetic, ISS, or R‐ISS. In the cytogenetic standard‐risk group, ISS I/II, and R‐ISS I/II, 13%, 23%, and 23% of patients with adverse survivals were identified.Conclusions: For the first time, this study confirmed the prognostic value of GEP markers outside clinical trials. Conventional prognostic models to define high‐risk MM are improved by the incorporation of GEP markers.
- 1 January 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (1) , 120-129
Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma
- 1 January 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (1) , 120-129
Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma
- Open Access
A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma
Many cancer drugs only benefit a subset of the patients that receive them, but are often associated with serious side effects. Predictive classification methods that can identify which patients will benefit from a specific treatment are therefore of great clinical utility. We here introduce a novel machine learning method to identify predictive gene expression signatures, based on the idea that patients who received different treatments but exhibit similar expression profiles can be used to model response to the alternative treatment. We use this method to predict proteasome inhibitor benefit in Multiple Myeloma (MM). In a dataset of 910 MM patients we identify a 14-gene expression signature that can successfully predict benefit to the proteasome inhibitor bortezomib, with a hazard ratio of 0.47 (p = 0.04) in class ‘benefit’, while in class ‘no benefit’ the hazard ratio is 0.91 (p = 0.68). Importantly, we observe a similar classification performance (HR class benefit = 0.46, p = 0.04) in an independent patient cohort which was moreover measured on a different platform, demonstrating the robustness of the signature. Moreover, we find that the genes in the discovered signature are essential, as no equivalent signature can be found when they are excluded from the analysis. Multiple genes in the signature are linked to working mechanisms of proteasome inhibitors or MM disease progression. In conclusion, our method allows for identification of gene expression signatures that can aid in treatment decisions for MM patients and provide insight into the biological mechanism behind treatment benefit.
Open AccessA robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma
Many cancer drugs only benefit a subset of the patients that receive them, but are often associated with serious side effects. Predictive classification methods that can identify which patients will benefit from a specific treatment are therefore of great clinical utility. We here introduce a novel machine learning method to identify predictive gene expression signatures, based on the idea that patients who received different treatments but exhibit similar expression profiles can be used to model response to the alternative treatment. We use this method to predict proteasome inhibitor benefit in Multiple Myeloma (MM). In a dataset of 910 MM patients we identify a 14-gene expression signature that can successfully predict benefit to the proteasome inhibitor bortezomib, with a hazard ratio of 0.47 (p = 0.04) in class ‘benefit’, while in class ‘no benefit’ the hazard ratio is 0.91 (p = 0.68). Importantly, we observe a similar classification performance (HR class benefit = 0.46, p = 0.04) in an independent patient cohort which was moreover measured on a different platform, demonstrating the robustness of the signature. Moreover, we find that the genes in the discovered signature are essential, as no equivalent signature can be found when they are excluded from the analysis. Multiple genes in the signature are linked to working mechanisms of proteasome inhibitors or MM disease progression. In conclusion, our method allows for identification of gene expression signatures that can aid in treatment decisions for MM patients and provide insight into the biological mechanism behind treatment benefit.
- Open Access
- 27 July 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-10
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Many cancer treatments are associated with serious side effects, while they often only benefit a subset of the patients. Therefore, there is an urgent clinical need for tools that can aid in selecting the right treatment at diagnosis. Here we introduce simulated treatment learning (STL), which enables prediction of a patient’s treatment benefit. STL uses the idea that patients who received different treatments, but have similar genetic tumor profiles, can be used to model their response to the alternative treatment. We apply STL to two multiple myeloma gene expression datasets, containing different treatments (bortezomib and lenalidomide). We find that STL can predict treatment benefit for both; a twofold progression free survival (PFS) benefit is observed for bortezomib for 19.8% and a threefold PFS benefit for lenalidomide for 31.1% of the patients. This demonstrates that STL can derive clinically actionable gene expression signatures that enable a more personalized approach to treatment.
- 27 July 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-10
Open AccessPredicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
Many cancer treatments are associated with serious side effects, while they often only benefit a subset of the patients. Therefore, there is an urgent clinical need for tools that can aid in selecting the right treatment at diagnosis. Here we introduce simulated treatment learning (STL), which enables prediction of a patient’s treatment benefit. STL uses the idea that patients who received different treatments, but have similar genetic tumor profiles, can be used to model their response to the alternative treatment. We apply STL to two multiple myeloma gene expression datasets, containing different treatments (bortezomib and lenalidomide). We find that STL can predict treatment benefit for both; a twofold progression free survival (PFS) benefit is observed for bortezomib for 19.8% and a threefold PFS benefit for lenalidomide for 31.1% of the patients. This demonstrates that STL can derive clinically actionable gene expression signatures that enable a more personalized approach to treatment.